Department of Endocrinology, Shijiazhuang People's Hospital, Shijiazhuang, China.
Department of Neurosurgery, Shijiazhuang People's Hospital, Shijiazhuang, China.
Medicine (Baltimore). 2024 Nov 29;103(48):e40713. doi: 10.1097/MD.0000000000040713.
To explore the clinical effects and adverse reactions of Bailing capsules combined with levothyroxine sodium for autoimmune thyroiditis, 70 patients with autoimmune thyroiditis were retrospectively enrolled and divided into the Bailing treatment group and the control, both consisting of 35 patients. The control group was treated with levothyroxine sodium alone, and the treatment group with Bailing capsules combined with levothyroxine sodium. The clinical efficacy, thyroid function indicators, antibodies and inflammatory indicators, and adverse drug reactions were analyzed. The total treatment effective rate was significantly (P = .04) higher in the treatment (94.29%) than in the control group (77.14%). After treatment, the levels of free triiodothyronine (8.69 ± 1.02 vs 6.70 ± 1.12 pmol/L) and free thyroxine (FT4) (20.05 ± 2.33 vs 13.00 ± 2.41 pmol/L) were significantly (P < .001) higher in the treatment group than those in the control group, the levels of thyroid peroxidase antibody (TPOAb) (298.70 ± 65.08 vs 735.15 ± 93.39 U/mL) and thyroglobulin antibodies (TgAb) (93.37 ± 21.10 vs 194.20 ± 37.48 U/mL) in the treatment group were significantly (P < .05) lower than those in the control group, and the interleukin-6 (IL-6) (82.83 ± 3.15 vs 97.17 ± 2.27 ng/L) and interleukin-17 (6.02 ± 0.67 vs 6.89 ± 0.72 ng/L) indicators in the treatment group were significantly (P < .05) lower than those in the control group. No significant (P = .393) difference was found in the adverse drug reaction. In conclusion, Bailing capsules combined with levothyroxine sodium are effective and safe for autoimmune thyroiditis, with good control of disease progression, improvement of thyroid function, reduction of thyroid function-related antibody level, and inhibition of inflammation.
为了探讨百灵胶囊联合左甲状腺素钠治疗自身免疫性甲状腺炎的临床效果及不良反应，回顾性纳入 70 例自身免疫性甲状腺炎患者，分为百灵治疗组和对照组，各 35 例。对照组给予左甲状腺素钠单独治疗，治疗组给予百灵胶囊联合左甲状腺素钠治疗。分析临床疗效、甲状腺功能指标、抗体和炎症指标以及药物不良反应。治疗组总有效率（94.29%）明显（P=0.04）高于对照组（77.14%）。治疗后，治疗组游离三碘甲状腺原氨酸（8.69±1.02 vs 6.70±1.12 pmol/L）和游离甲状腺素（FT4）（20.05±2.33 vs 13.00±2.41 pmol/L）水平明显高于对照组（P<0.001），治疗组甲状腺过氧化物酶抗体（TPOAb）（298.70±65.08 vs 735.15±93.39 U/mL）和甲状腺球蛋白抗体（TgAb）（93.37±21.10 vs 194.20±37.48 U/mL）水平明显低于对照组（P<0.05），治疗组白细胞介素-6（IL-6）（82.83±3.15 vs 97.17±2.27 ng/L）和白细胞介素-17（IL-17）（6.02±0.67 vs 6.89±0.72 ng/L）水平明显低于对照组（P<0.05）。两组药物不良反应发生率比较差异无统计学意义（P=0.393）。结论 百灵胶囊联合左甲状腺素钠治疗自身免疫性甲状腺炎疗效确切，安全性好，能有效控制疾病进展，改善甲状腺功能，降低甲状腺功能相关抗体水平，抑制炎症。
